Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $22.2952W HIGH $42.81
Volume
6.71 M
Value Traded
2.82 M
Short % Float
7.51%
-0.45%Week
+4.46%1 Month
+70.35%3 Month
+31.35%6 Month
+31.6%5 Year
-99.18%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
522.33 M
EPS (TTM)
1.65
P/E Ratio
26.51
Ent. Value
572.18 M
Total Shares
12.39 M
Float Shares
12.19 M
Insiders
0.29%
Institutions
42.16%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
XOMA Catalyst Timeline
Dated clinical, regulatory and corporate events for XOMA Royalty Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for XOMA Royalty Corporation
436Total events
11Upcoming
155Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Timing GuidanceersodetugPresentation
Product launch of ersodetug for HI expected in 2H26
Hyperinsulinism (HI)source ↗
◆Timing GuidancevolixibatPresentation
Data announcement for volixibat in PSC expected in 2Q26
Primary Sclerosing Cholangitis (PSC)source ↗
◆Topline ReadoutvolixibatClinical Data
Phase 2b data from volixibat in PSC expected in Q2 2026
PSCsource ↗
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results and business update webcast
◆AcquisitionCorporate
XOMA Royalty completes acquisition of Generation Bio via tender offer and merger
▼Equity OfferingCorporate
Tender offer for Generation Bio shares at $4.2913 per share plus CVR
▲CHMP Positive OpinionOJEMDAEx-US Regulatory
CHMP issued positive opinion recommending conditional marketing authorization of OJEMDA
◆Topline ReadoutseralutinibClinical Data
Gossamer Bio expects topline results from Phase 3 PROSERA trial of seralutinib in PAH
pulmonary atrial hypertensionsource ↗
◆FDA Feedback ReceivedersodetugFDA Meeting
Rezolute to meet with FDA in Q1 2026 to discuss next steps for ersodetug
congenital hyperinsulinismsource ↗
◆AcquisitionCorporate
XOMA Royalty subsidiary XRA 5 Corp. to acquire Mural Oncology for $2.035-$2.24 per share
●Quarterly UpdateCorporate
Cash, cash equivalents, and restricted cash as of Dec 31, 2025 ~$133M
▲Partnership / LicenseCorporate
XOMA Royalty and Takeda execute strategic royalty sharing transaction and amend existing agreement for mezagitamab
▼Topline ReadoutersodetugClinical Data
Topline results from Phase 3 sunRIZE study of ersodetug in congenital hyperinsulinism
congenital hyperinsulinismsource ↗
▼Primary Endpoint MissedersodetugClinical Data
Phase 3 sunRIZE study failed primary endpoint
congenital hyperinsulinismsource ↗
◆Topline ReadoutersodetugClinical Data
Rezolute to announce topline data from Phase 3 sunRIZE trial of ersodetug in congenital HI
congenital hyperinsulinismsource ↗
▲Partnership / LicenseCorporate
XOMA amended collaboration with Takeda for royalties and milestones on nine assets
▲AcquiredCorporate
XenoTherapeutics completed acquisition of ESSA Pharma (XOMA as structuring agent)
▲First Patient DosedmezagitamabTrial
First patient dosed in Takeda's Phase 3 trial of mezagitamab for IgA Nephropathy
IgA Nephropathysource ↗
▲Interim AnalysisOvapreneTrial
Daré Biosciences announced positive interim safety and efficacy results from Phase 3 trial of Ovaprene
contraceptionsource ↗
◆AcquisitionCorporate
Extraordinary General Meeting of Shareholders reconvened to November 7, 2025
◆Topline ReadoutseralutinibClinical Data
Phase 3 topline data readout expected
pulmonary arterial hypertensionsource ↗
▲Milestone PaymentOJEMDACorporate
Day One OJEMDA NDA filing in Japan triggered $2 million milestone in 4Q25
▲Trial InitiationseralutinibTrial
Gossamer Bio activated first clinical site for Phase 3 SERANATA study of seralutinib in PH-ILD
pulmonary hypertension associated with interstitial lung diseasesource ↗
▲Product LaunchPost-Market
Daré Bioscience makes DARE to PLAY Sildenafil Cream available commercially via prescription
female sexual arousal disordersource ↗
Past FDA Catalysts and PDUFA Decisions
How XOMA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Seralutinib | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D28 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
12
Drugs Scored
-
rNPV / MCap
XOMA Royalty Corporation faces pipeline headwinds (28/100), with 12 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every XOMA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Montano Maricel PereaOfficer (Chief Legal Officer) | Other | -42,306 | $0.00 | 07/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XOMA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 8.3 % (219.2 %) | 322.71 M | 7.59 M | 193.14% ( 5.00 M) |
XOMA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XOMA ranks across every disease it competes in
Competitive Position is a premium feature
See how XOMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXOMA News
About XOMA Royalty Corporation
Headquarters2200 POWELL STREET, EMERYVILLE, CA, 94608
BIOPHARMAWATCH ELITE PLUS
Trade the next XOMA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime